AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Eleftha 375mg Injection

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Trastuzumab (375mg)

Overview Eleftha 375mg Injection

Oncaspar 375mg Injection treats breast and gastric cancers by targeting and destroying HER2-positive cancer cells. Administered intravenously by a healthcare professional, the dosage and frequency are determined individually by your physician based on your specific condition and may adjust over time. Strict adherence to your doctor's prescribed regimen is crucial; improper use or overdose can lead to severe adverse reactions. While therapeutic benefits may not be immediately apparent (requiring weeks or months), discontinue use only under your doctor's instruction. Common side effects include nausea, headache, skin rash, sleep disturbances, and infections. This medication can lower blood cell counts, increasing infection risk; regular blood tests are necessary to monitor blood cell levels, heart function, liver health, and uric acid. Report shortness of breath, cough, chills, or limb swelling to your doctor immediately. Inform your medical team of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and lactation; reliable contraception for both partners is essential throughout treatment.

Primary Ingredients of Eleftha 375mg Injection

No text provided to rephrase.

Uses of Eleftha 375mg Injection

Cancers affecting the breast and stomach.

Major Benefits of Eleftha 375mg Injection:

Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.

Common Side effects of Eleftha 375mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Eleftha 375mg Injection:

Administering this medication will be handled by your healthcare provider; self-medication is strictly prohibited.

How Eleftha 375mg Injection works:

Oncaspar, a 375mg injection formulated as a recombinant IgG1 monoclonal antibody, targets HER2 (human epidermal growth factor receptor 2) receptors. By binding to these receptors, it prevents the uncontrolled growth of breast and gastric cancer cells. This mechanism halts HER2-driven proliferation and disrupts associated oncogenic signaling cascades.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concomitant use of Eleftha 375mg Injection and alcohol may result in pronounced somnolence.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Eleftha 375mg Injection during pregnancy is contraindicated due to established harm to the fetus. Exceptions may exist in critical circumstances where a physician deems the potential advantages outweigh the known risks. Physician consultation is mandatory.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Eleftha 375mg Injection while breastfeeding is likely inadvisable. Available human data indicates a potential for the medication to transfer to breast milk, posing a risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The effect of Eleftha 375mg Injection on driving ability is undetermined. Refrain from operating a vehicle should you experience symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

The use of Eleftha 375mg Injection in individuals with kidney impairment appears to pose minimal risk. Existing evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.

LiverLiverCONSULT YOUR DOCTOR

Data regarding the administration of Eleftha 375mg Injection to individuals with hepatic impairment is scarce. Physician consultation is recommended.

What if you forget to take Eleftha 375mg Injection :

Omit a scheduled Eleftha 375mg Injection? Seek your physician's advice.

Facts to Know About Eleftha 375mg Injection

LabelValue
Chemical Type Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Treatments
Action class Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Eleftha 375mg Injection

Eleftha 375mg Injection may cause side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, unusual bruising or bleeding, stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea or vomiting, loss of appetite, rapid heartbeat, discolored or decreased urine output, painful urination, and other signs of infection. Contact your doctor immediately if you experience any of these symptoms.
Effective contraception should be used by women of childbearing age throughout Eleftha 375mg Injection therapy and for seven months afterward. Pregnancy planning can resume seven months post-treatment.
Early-stage breast cancer patients should receive Eleftha 375mg Injection for one year, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Eleftha 375mg Injection does not require fasting beforehand. Administration must be by a healthcare professional, under the supervision of a doctor experienced in cancer chemotherapy.
Eleftha 375mg Injection is available in two formulations: intravenous (IV) infusion and subcutaneous (SC) injection. Always verify the product label to ensure correct administration. The IV formulation is for intravenous infusion only and should not be given subcutaneously. Your doctor can determine if switching between IV and SC Eleftha 375mg Injection is appropriate for your treatment.
Eleftha 375mg Injection, a monoclonal antibody, targets the HER2 protein found on some cancer cells. Because it works by binding to HER2 to inhibit cancer growth, it's only effective in patients with HER2-positive cancer; it's ineffective and shouldn't be used in those with HER2-negative cancer.
Using Eleftha 375mg Injection with anthracycline cancer drugs (like doxorubicin) can harm your heart. Your doctor must assess your heart health before and during treatment.
Cardiac evaluations are necessary at treatment initiation, every three months during treatment, and every six months post-treatment for 24 months following the final Eleftha 375mg Injection. Patients with pre-existing cardiac conditions require evaluation every twelve weeks.
Eleftha 375mg Injection
16,189